| Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy (NCT02362230) | Sun Yat-sen University | 2015-01-01 |
| Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab (NCT02338245) | ASLAN Pharmaceuticals | 2014-12-29 |
| Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer (NCT02263495) | Asan Medical Center | 2014-12-19 |
| Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer (NCT02129556) | ETOP IBCSG Partners Foundation | 2014-12-01 |
| Everolimus trIal for Advanced prememopausaL Breast Cancer Patients (NCT02313051) | Chinese Academy of Medical Sciences | 2014-12-01 |
| Retroprospective Real Life Observatory of Eribulin (NCT02393287) | Institut Cancerologie de l'Ouest | 2014-11-01 |
| Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies (NCT02238509) | Consorzio Oncotech | 2014-11-01 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| SOLTI Breast Cancer Molecular Screening Program (AGATA) (NCT02445482) | SOLTI Breast Cancer Research Group | 2014-10-01 |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer (NCT02202746) | Clovis Oncology, Inc. | 2014-09-09 |
| Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients (NCT02175446) | Consorzio Oncotech | 2014-09-01 |
| Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer (NCT02361112) | Jiangsu HengRui Medicine Co., Ltd. | 2014-08-01 |
| AR and ER Imaging in Metastatic Breast Cancer (NCT01988324) | University Medical Center Groningen | 2014-08-01 |
| Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks (NCT02051218) | Swiss Cancer Institute | 2014-07-16 |
| Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 (NCT03275311) | UNICANCER | 2014-07-01 |
| A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread (NCT02102490) | Eli Lilly and Company | 2014-06-10 |
| BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer (NCT03603197) | Meabco A/S | 2014-06-05 |
| A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer (NCT02144012) | Hoffmann-La Roche | 2014-06-01 |
| Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer (NCT02066532) | Dawn L. Hershman | 2014-06-01 |
| STAR Cape+BKM120 MBC With Brain Met (NCT02000882) | US Oncology Research | 2014-05-29 |
| PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer (NCT02423603) | Queen Mary University of London | 2014-05-14 |
| Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes (NCT02101879) | Rambam Health Care Campus | 2014-05-01 |
| PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment (NCT02864030) | Oncologia Medica dell'Ospedale Fatebenefratelli | 2014-05-01 |
| A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer (NCT02163694) | AbbVie | 2014-04-08 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (NCT02299999) | UNICANCER | 2014-04-07 |
| AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. (NCT02102165) | Jules Bordet Institute | 2014-04-01 |
| Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy (NCT02329639) | University of Pisa | 2014-04-01 |
| A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer (NCT02137083) | Fudan University | 2014-04-01 |
| Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors (NCT02028507) | Spanish Breast Cancer Research Group | 2014-03-13 |
| Halaven Patient Registry (Metastatic Breast Cancer, MBC) (NCT03245112) | Chang Gung Memorial Hospital | 2014-03-03 |
| Rapid Medical Donation Programme for Breast Cancer (NCT02126800) | Royal Marsden NHS Foundation Trust | 2014-03-01 |
| Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane (NCT02109913) | Amsterdam UMC, location VUmc | 2014-03-01 |
| Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer (NCT02470819) | Avera McKennan Hospital & University Health Center | 2014-03-01 |
| Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients (NCT02018419) | Mirror Biologics, Inc. | 2014-03-01 |
| Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (NCT02064829) | Sorrento Therapeutics, Inc. | 2014-03-01 |
| Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) (NCT01990209) | SCRI Development Innovations, LLC | 2014-03-01 |
| A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) (NCT01989676) | Pfizer | 2014-02-24 |
| Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca (NCT02041429) | Dana-Farber Cancer Institute | 2014-02-01 |
| BP-C1 in Metastatic Breast Cancer Patients (NCT01861509) | Meabco A/S | 2014-01-19 |
| The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer (NCT02072512) | Hospital Affiliated to Military Medical Science, Beijing | 2014-01-01 |
| Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer (NCT02344550) | Asan Medical Center | 2014-01-01 |
| Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer (NCT04411966) | Chang Gung Memorial Hospital | 2014-01-01 |
| Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (NCT01989780) | Japan Breast Cancer Research Group | 2014-01-01 |
| 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. (NCT02000596) | University of Maryland, Baltimore | 2014-01-01 |
| Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer (NCT02207335) | Tianjin Medical University Cancer Institute and Hospital | 2013-12-01 |
| Patient Derived Breast Cancer Xenografts (NCT01750164) | Dartmouth-Hitchcock Medical Center | 2013-12-01 |
| Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer (NCT02207361) | Tianjin Medical University Cancer Institute and Hospital | 2013-12-01 |
| Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer (NCT01349088) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-12-01 |
| Biweekly Docetaxel in Patients With Metastatic Breast Cancer. (NCT02041351) | Centro Universitario contra el Cáncer | 2013-11-01 |
| First Line Metastatic Breast Cancer Treatment (ESMERALDA) (NCT01941407) | ARCAGY/ GINECO GROUP | 2013-11-01 |
| T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer (NCT02073916) | Jenny C. Chang, MD | 2013-10-01 |
| Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) (NCT01942135) | Pfizer | 2013-09-26 |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (NCT01881230) | Celgene | 2013-09-26 |
| IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins (NCT01939847) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2013-09-19 |
| Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer (NCT02008994) | Sanford Health | 2013-09-01 |
| Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer (NCT01985893) | Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V. | 2013-09-01 |
| Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (NCT01912963) | Dana-Farber Cancer Institute | 2013-09-01 |
| A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer (NCT01973309) | OncoMed Pharmaceuticals, Inc. | 2013-09-01 |
| IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer (NCT01957332) | University Medical Center Groningen | 2013-08-30 |
| Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer (NCT01975597) | University of Michigan Rogel Cancer Center | 2013-08-01 |
| Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer (NCT01939418) | National Cancer Center, Korea | 2013-08-01 |
| A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer (NCT01919749) | Translational Drug Development | 2013-08-01 |
| Ixabepilone and SBRT For Metastatic Breast Cancer (NCT01818999) | University of Texas Southwestern Medical Center | 2013-08-01 |
| Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes (NCT01910844) | Centre Jean Perrin | 2013-07-01 |
| Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes (NCT01910870) | Centre Jean Perrin | 2013-07-01 |
| Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer (NCT01837095) | Polyphor Ltd. | 2013-06-01 |
| Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer (NCT02020291) | WntResearch AB | 2013-06-01 |
| Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI (NCT01797120) | PrECOG, LLC. | 2013-05-31 |
| BIG Molecular Screening Feasibility Study (NCT02094742) | Jules Bordet Institute | 2013-05-01 |
| Breast Cancer Molecular Analysis Protocol (NCT01855503) | Yale University | 2013-05-01 |
| ABC Survey - do we Meet the Needs of Patients With Advanced Breast Cancer? (NCT02051010) | Cancer Trials Ireland | 2013-05-01 |
| cMet CAR RNA T Cells Targeting Breast Cancer (NCT01837602) | University of Pennsylvania | 2013-04-01 |
| Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index (NCT01701050) | Janssen Diagnostics, LLC | 2013-04-01 |
| Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). (NCT02210364) | PharmaMar | 2013-04-01 |
| The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel (NCT01814150) | Gottfried Maya | 2013-04-01 |
| Phase II Study of GTx024 in Women With Metastatic Breast Cancer (NCT01616758) | GTx | 2013-04-01 |
| Capecitabine With Digoxin for Metastatic Breast Cancer (NCT01887288) | Western Regional Medical Center | 2013-04-01 |
| Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (NCT01835236) | Swiss Cancer Institute | 2013-03-03 |
| Clinical Value of 89Zr-trastuzumab PET (NCT01832051) | University Medical Center Groningen | 2013-03-01 |
| BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment (NCT03789019) | Meabco A/S | 2013-02-22 |
| A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer (NCT01656538) | Canadian Cancer Trials Group | 2013-02-20 |
| Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer (NCT01792050) | NewLink Genetics Corporation | 2013-02-01 |
| A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes (NCT01589159) | Tao OUYANG | 2013-01-01 |
| BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer (NCT02783794) | Meabco A/S | 2012-12-24 |
| Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study (NCT01715155) | AstraZeneca | 2012-12-01 |
| Polymorphism Interaction to Predict Bevacizumab Efficacy (NCT01935102) | University of Pisa | 2012-12-01 |
| Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer (NCT01937507) | Western Regional Medical Center | 2012-12-01 |
| Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway (NCT01653366) | Dartmouth-Hitchcock Medical Center | 2012-12-01 |
| Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients (NCT01802970) | Baylor Research Institute | 2012-12-01 |
| Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer (NCT01928680) | Chinese Academy of Medical Sciences | 2012-11-01 |
| Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer (NCT01733628) | Spanish Breast Cancer Research Group | 2012-10-23 |
| A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi (NCT01633060) | Novartis Pharmaceuticals | 2012-10-03 |
| A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer. (NCT01785992) | Imperial College London | 2012-10-01 |
| Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer (NCT01663727) | Hoffmann-La Roche | 2012-08-27 |
| A Study of LY3023414 in Participants With Advanced Cancer (NCT01655225) | Eli Lilly and Company | 2012-07-31 |
| Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer (NCT01596751) | Hope Rugo, MD | 2012-07-12 |
| Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors (NCT01576666) | Novartis Pharmaceuticals | 2012-07-01 |
| Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer (NCT01654185) | Xichun Hu | 2012-07-01 |
| ErbB2 Positive Metastatic Breast Cancer (NCT01658358) | China Medical University Hospital | 2012-07-01 |
| Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors (NCT01640665) | Yale University | 2012-07-01 |